ClinicalTrials.gg

Program

tenofovir alafenamide

Also written as “E/C/F/TAF”, “TAF” and “B/F/TAF”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · HIV Infections · Hepatitis · Coinfection, led by 7 companies.

Furthest: phase 4, since Oct 23, 202361 company-led studies, 10 open or runningNext primary completion: Jun 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences499 open or runningphase 4since Oct 23, 2023May 13, 2002Jun 2027phase 4 · NCT06337032
Johnson & Johnson70 open or runningphase 3since Oct 17, 2014Oct 17, 2014none ahead
Henan Genuine Biotech10 open or runningphase 1since May 13, 2025May 13, 2025none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Sep 9, 2024Sep 9, 2024none ahead
New Discovery10 open or runningphase 4since Dec 6, 2019Dec 6, 2019none ahead
The Crofoot Research Center10 open or runningphase 4since May 12, 2020May 12, 2020none ahead
Xiamen Amoytop Biotech11 open or runningno phasesince Nov 24, 2024Nov 24, 2024May 31, 2029NCT06707922

Also a collaborator on its studies: Merck and F-star Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Dec 14, 2011.

  1. Dec 6, 2019New Discovery’s first study: phase 4 study in Hepatitis B, ChronicNew to New DiscoveryNew Discovery · NCT04201808 · 100 enrolled · China
  2. Jan 21, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04236453 · 16 enrolled · Netherlands
  3. May 12, 2020The Crofoot Research Center’s first study: phase 4 study in Acquired Immunodeficiency SyndromeNew to The Crofoot Research CenterThe Crofoot Research Center · NCT04388904 · 75 enrolled · United States
  4. Dec 3, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04661397 · 37 enrolled · Netherlands
  5. Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionGilead Sciences · NCT04994509 · 5,368 enrolled · South Africa, Uganda
  6. Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
  7. Mar 22, 2024Phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032 · 350 planned · Argentina, Panama, South Africa and more
  8. Sep 9, 2024Humanis Saglık Anonim Sirketi’s first study: phase 1 study in Chronic Hepatitis B in Adults and Paediatric PatientsNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06592300 · 42 enrolled · India
  9. Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
  10. Nov 24, 2024Xiamen Amoytop Biotech’s first study: no phase study in Hepatitis B, ChronicNew to Xiamen Amoytop BiotechXiamen Amoytop Biotech · NCT06707922 · 350 planned · China
  11. May 13, 2025Henan Genuine Biotech’s first study: phase 1 study in HealthyNew to Henan Genuine BiotechHenan Genuine Biotech · NCT07002268 · 15 enrolled · China
  12. Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
  13. Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
  14. Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more

Ahead

  1. Jun 2027Primary completion: phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032
  2. Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
  3. Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
  4. May 31, 2029Primary completion: no phase study in Hepatitis B, ChronicXiamen Amoytop Biotech · NCT06707922

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07708727HIV-1-infection · United States, Canada, Germany and more3RecruitingGilead SciencesOct 2030700
NCT07645287HIV-1-infection · United States, Australia, Canada and more2RecruitingGilead SciencesAug 2027175
NCT07055451HIV-1-infection · United States, South Africa1Active, not recruitingGilead SciencesMar 202816
NCT07002268Healthy · China1CompletedHenan Genuine BiotechMay 4, 202215
NCT06707922Hepatitis B, Chronic · China–By invitationXiamen Amoytop BiotechMay 31, 2029350
NCT06630286HIV-1-infection · United States, Argentina, Australia and more3Active, not recruitingGilead SciencesApr 17, 2026609
NCT06592300Chronic Hepatitis B in Adults and Paediatric Patients · India1CompletedHumanis Saglık Anonim SirketiAug 2, 202442
NCT06337032HIV-1-infection · Argentina, Panama, South Africa and more4RecruitingGilead SciencesJun 2027350
NCT06104306HIV-1-infection · United States, Canada, France4CompletedGilead SciencesJan 29, 202533
NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda3Active, not recruitingGilead SciencesMay 27, 20245,368
NCT04661397Healthy · Netherlands1CompletedJohnson & JohnsonJul 2, 202137
NCT04388904Acquired Immunodeficiency Syndrome · United States4CompletedThe Crofoot Research CenterApr 5, 202475
NCT04236453Healthy · Netherlands1TerminatedJohnson & JohnsonApr 10, 202016
NCT04201808Hepatitis B, Chronic · China4UNKNOWNNew DiscoverySep 30, 2023100
NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico2CompletedGilead SciencesOct 5, 2021183
NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand1CompletedGilead SciencesJul 21, 202262
NCT03739866HIV-1 Infection · United States1CompletedGilead SciencesNov 14, 201953
NCT03631732HIV-1 Infection · United States3CompletedGilead SciencesAug 12, 2019496
NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more3CompletedGilead SciencesFeb 25, 2022244
NCT03434353Hepatitis B, Chronic · Hong Kong, Korea, Republic of2TerminatedGilead SciencesJan 20, 2020123
NCT03405935HIV-1 Infection · Belgium, France, Italy and more3CompletedGilead SciencesNov 20, 201886
NCT03180619Hepatitis B, Chronic · United States, Canada, Hong Kong and more2CompletedGilead SciencesMar 27, 2019124
NCT03110380HIV-1-infection · United States, Austria, Canada and more3CompletedGilead SciencesDec 4, 2018567
NCT02984852Healthy · United States1CompletedJohnson & JohnsonFeb 201730
NCT02932150Hepatitis B, Chronic · United States, Belgium, Hong Kong and more2Active, not recruitingGilead SciencesOct 27, 2026150
NCT02881320HIV-1 Infection · United States, South Africa, Thailand and more3Active, not recruitingGilead SciencesMar 24, 2025177
NCT02862548Hepatitis B, Chronic · New Zealand2CompletedGilead SciencesFeb 8, 201851
NCT02842086Pre-Exposure Prophylaxis of HIV-1 Infection · United States, Austria, Canada and more3TerminatedGilead SciencesJan 31, 20195,399
NCT02836249Hepatitis · China3CompletedGilead SciencesMar 21, 2017181
NCT02836236Hepatitis · China3CompletedGilead SciencesApr 5, 2017155
NCT02707601Hepatitis C · United States, Puerto Rico3CompletedGilead SciencesSep 14, 2017150
NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more3CompletedGilead SciencesOct 9, 2017472
NCT02616029HIV-1 Infection · United States, France, Germany and more3CompletedGilead SciencesOct 11, 201866
NCT02616783HIV-1 Infection · Belgium, France, Italy and more3CompletedGilead SciencesFeb 21, 2018167
NCT02605954HIV-1 Infection · United States, France, Germany and more3CompletedGilead SciencesJun 14, 2017275
NCT02607956HIV-1 Infection · United States, Australia, Belgium and more3CompletedGilead SciencesMay 12, 2017657
NCT02600819Kidney Failure, Chronic · United States, Austria, France and more3CompletedGilead SciencesSep 29, 201755
NCT02578550Acquired Immunodeficiency Syndrome · Netherlands1CompletedJohnson & JohnsonFeb 2016126
NCT02475135Acquired Immunodeficiency Syndrome · Belgium1CompletedJohnson & JohnsonAug 14, 201572
NCT02469246HIV-1 Infection · United States, Belgium, Canada and more3CompletedGilead SciencesDec 11, 2017567
NCT02431247Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more3CompletedJohnson & JohnsonMar 2, 2017725
NCT02397694HIV-1 Infection · United States2CompletedGilead SciencesNov 30, 201598
NCT02296853Hepatitis B · United States, Germany, New Zealand1CompletedGilead SciencesApr 17, 201520
NCT02276612HIV · United States, South Africa3CompletedGilead SciencesNov 10, 201660
NCT02269917Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more3CompletedJohnson & JohnsonFeb 20171,149
NCT02121795HIV-1 Infection · United States, Belgium, Canada and more3CompletedGilead SciencesAug 12, 2015668
NCT02071082Coinfection · United States, Canada, Japan3CompletedGilead SciencesJan 23, 201579
NCT02016924Acquired Immunodeficiency Syndrome · United States, Argentina, South Africa and more3Active, not recruitingGilead SciencesJun 13, 2025133
NCT01967940HIV Infections · United States, Dominican Republic, Russian Federation and more3CompletedGilead SciencesMay 21, 201555
NCT01968551HIV Infections · United States, Canada3CompletedGilead SciencesJul 21, 2015158
NCT01940471Hepatitis · United States, Australia, Bulgaria and more3CompletedGilead SciencesNov 16, 2015875
NCT01940341Hepatitis · United States, Australia, Canada and more3CompletedGilead SciencesSep 30, 2015426
NCT01854775Acquired Immunodeficiency Syndrome · United States, South Africa, Thailand and more3CompletedGilead SciencesMay 11, 2020129
NCT01818596HIV Infections · United States, Australia, Dominican Republic and more3CompletedGilead SciencesJul 31, 2014252
NCT01815736HIV Infections · United States, Australia, Austria and more3CompletedGilead SciencesMar 16, 20151,443
NCT01797445HIV Infections · United States, Canada, Dominican Republic and more3CompletedGilead SciencesSep 19, 2014872
NCT01780506HIV Infections · United States, Australia, Austria and more3CompletedGilead SciencesAug 26, 2014872
NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more1CompletedGilead SciencesApr 201351
NCT01565850Acquired Immunodeficiency Syndrome · United States, Puerto Rico2CompletedGilead SciencesJan 2013153
NCT01497899Acquired Immunodeficiency Syndrome · United States, Puerto Rico2CompletedGilead SciencesOct 17, 2012279

How it is read

Names in the registry

  • “E/C/F/TAF”, 17 entries
  • “TAF”, 12 entries
  • “B/F/TAF”, 10 entries
  • “F/TAF”, 8 entries
  • “B/F/TAF (TOS)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.